908 Devices (NASDAQ: MASS) reported record third-quarter revenue of $19 million, up 35% from a year earlier, and raised the low end of its 2026 revenue forecast as demand for its detection devices grew internationally. The company now expects full-year revenue of $68.5 million to $70 million, representing growth of 22% to 25% over 2025. Chief
908 Devices delivered strong Q3 results with 35% year-over-year revenue growth, beating analyst estimates, and achieving a record 308 device placements. Management raised the low end of its 2026 revenue guidance range to $68.5 million while reducing losses from year ago levels. MASS improved its financial profile, generating $1.3 million in free cash flow year to date, and ended Q3 with $99.1 million cash and no debt.
908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript
908 Devices NASDAQ: MASS reported record third-quarter revenue of $19 million, up 35% from a year earlier, and raised the low end of its 2026 revenue forecast as demand for its detection devices grew internationally.
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.15 per share a year ago.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026. "We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founde.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced that management will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 4:00 p.m. ET. A live webcast of the fireside chat will be available in the “Investors” section of the company's website at: www.908devices.c.
We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the third quarter 2026 before market open on Tuesday, November 10, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors”.
TTM Technologies (NASDAQ: TTMI - Get Free Report) and 908 Devices (NASDAQ: MASS - Get Free Report) are both technology companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability. Analyst Ratings This is a breakdown of recent